Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of Ruconest for prevention of acute kidney injury after NSTEMI coronary angiography
MOH_2022-03-29_010613Phase 2Completed
- Sponsor
- Pharming Group
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of c1-esterase inhibitor in acute kidney failure (AKF) (4 arms), sponsored by Pharming Group. Started Mar 2022; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on MOH_2022-03-29_010613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-29_010613.